Annual Report 2014 of Beximco Pharmaceuticals Limited

It is a broadly described annual report of Beximco Pharmaceuticals Limited in the year of 2014. Gross profit of the company rose to Taka. 5,104.2 million in 2014 an increase of 5.5% compared to previous year. The gross profit as the percentage of sales remains more or less stable- 45.5% as against 46.1% in 2013; the declining is due to higher depreciation charge and increased overhead cost. Profit after tax also increased to Taka. 1,528.3 million in 2014, compared to Taka. 1,404.8 million in 2013 marking a rise of 8.8%. The domestic sales of the Company in 2014, for the first time, crossed ten billion marks to reach Taka. 10,706.4 million by the end of the year. This is an appreciable 9.0% growth over Taka. 9,819.4 million in 2013. The revenue from export sales in 2014 was Taka. 500.4 million. This is lower than Taka. 671.3 million exports in 2013.

The Board of Directors is pleased to recommend 10% Cash Dividend i.e. Tk. 1 per share and 5% Stock Dividend i.e. 5 shares for every 100 shares held for the year 2014 for onward approval in the Annual General Meeting. These financial statements are presented in Bangladesh Taka (Taka/Tk/BDT) which is the company’s functional currency. All financial information presented in Taka has been rounded off to the nearest Taka.

More Annual Report of Beximco Pharmaceuticals Limited :